-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Sonoma Pharmaceuticals, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q2 2022 to Q2 2023.
- Sonoma Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $90K.
- Sonoma Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$196K, a 494% decline from 2022.
- Sonoma Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$33K, a 90.1% increase from 2021.
- Sonoma Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$332K, a 135% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)